Monopar Therapeutics Inc.
MNPR
$60.63
$0.020.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.14% | -51.29% | -40.11% | 6.53% | 75.97% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 130.47% | -64.74% | -14.09% | 3.56% | -74.38% |
| Change in Net Operating Assets | -132.86% | 482.13% | 156.63% | 102.26% | -204.11% |
| Cash from Operations | -3.08% | -61.21% | -94.03% | 80.98% | -183.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 91.02% | -2,825.15% | -279.06% | 464.43% | 97.73% |
| Cash from Investing | 91.02% | -2,825.15% | -279.06% | 464.43% | 97.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 2,718,476.60% | -69.48% | -99.97% |
| Repurchase of Common Stock | 47.96% | 98.91% | -10,901.71% | -145.31% | -95.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 47.96% | -100.42% | 29,264.02% | -173.81% | -100.21% |
| Foreign Exchange rate Adjustments | -131.76% | 24,775.00% | 115.38% | -2,500.00% | 97.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.89% | -174.67% | 42,188.50% | 96.57% | -115.34% |